Callisto (KAL) Receives Delisting Notification From AMEX; Receives 'Going Concern' From Auditor
Callisto Pharmaceuticals, Inc. (AMEX: KAL), announced today that on April 7, 2008, it received notice from the American Stock Exchange indicating that AMEX intends to strike the Company’s common stock from listing on AMEX by filing a delisting application with the Securities and Exchange Commission.
Callisto also announced today that the audit report of BDO Seidman, LLP, contained in its December 31, 2007 financial statements included in Callisto's Form 10-K filed on March 28, 2008, contained a going-concern qualification.
Callisto Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development of drugs to treat gastrointestinal diseases and cancer. [SM]
Callisto also announced today that the audit report of BDO Seidman, LLP, contained in its December 31, 2007 financial statements included in Callisto's Form 10-K filed on March 28, 2008, contained a going-concern qualification.
Callisto Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development of drugs to treat gastrointestinal diseases and cancer. [SM]
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
- Coeur d’Alene (CDE) Announces Resumption of Full Production at Palmarejo Mine
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
